Genovis AB - Bioscience tools and services

A bit of a monologue here. Oh well, at least I won’t start arguing with myself.
The annual report provides more detail on the reflections I shared above.
I hope to get answers from the AGM to at least these:

  • how much of the 2025 growth came from ADC? (core revenue +17%, currency-adjusted +23%)
  • when will the first milestone payment arrive?
  • what will be Sequrna’s realistic contribution to the results?
  • are there new licensing agreements in the pipeline?
  • is a share issue needed?
4 Likes